BIONDVAX PHARMACEUTICALS-ADR (BVXV) Forecast, Price Target & Analyst Ratings
NASDAQ:BVXV • US09073Q2049
1.36 USD
+0.05 (+3.82%)
At close: Sep 6, 2023
1.38 USD
+0.02 (+1.47%)
After Hours: 9/6/2023, 8:00:01 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BIONDVAX PHARMACEUTICALS-ADR (BVXV).
Forecast Snapshot
Consensus Price Target
$39.78
+ 2,825.00% Upside
Next Earnings Forecast
Release DateN/A
PeriodQ3 / 2023
EPS Estimate-$1.01
Revenue Estimate
ChartMill Buy Consensus
82.86%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$39.78
Upside
+ 2,825.00%
From current price of $1.36 to mean target of $39.78, Based on 7 analyst forecasts
Low
$8.08
Median
$39.78
High
$73.50
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
7 Wall Street analysts provided a forecast for the next 12 months for BVXV. The average price target is 39.78 USD. This implies a price increase of 2825% is expected in the next year compared to the current price of 1.36.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.86%
BVXV was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about BVXV.
In the previous month the buy percentage consensus was at a similar level.
BVXV was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2022-01-26 | Aegis Capital | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateN/A
PeriodQ3 / 2023
EPS Estimate-$1.01
Revenue Estimate
Revenue Q2QN/A
EPS Q2Q-10,198.00%
Number of Analysts3
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | ||||||||
| EBITDA YoY % growth | -10.67M | -11.28M -5.72% | -23.22M -105.85% | -76.81M -230.79% | -76.7M 0.14% | 9.77M 112.74% | -8.878M -190.87% | N/A | N/A | N/A | |
| EBIT YoY % growth | -11.3M | -11.9M -5.31% | -23.66M -98.82% | -77.07M -225.74% | -78.35M -1.66% | 7.33M 109.36% | -9.516M -229.83% | N/A -43.64% | N/A 6.03% | N/A -58.82% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A 98.72% | N/A -1,200.00% | N/A 61.54% | N/A 104.90% | -1.26 -5,136.00% | N/A -240.27% | N/A 99.29% | N/A -8,400.00% | N/A 92.16% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q3 / 23 | Q4 / 23 | |
|---|---|---|
| EPS Q2Q % growth | -1.01 -10,198.00% | -1.13 -1,010.00% |
| Revenue Q2Q % growth | ||
| EBITDA Q2Q % growth | N/A | N/A |
| EBIT Q2Q % growth | -2.907M -384.39% | -3.06M 4.00% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
24.98%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
BIONDVAX PHARMACEUTICALS-ADR / BVXV Forecast FAQ
What is the average price target for BIONDVAX PHARMACEUTICALS-ADR (BVXV) stock?
7 analysts have analysed BVXV and the average price target is 39.78 USD. This implies a price increase of 2825% is expected in the next year compared to the current price of 1.36.
What are the consensus estimates for BIONDVAX PHARMACEUTICALS-ADR (BVXV) next earnings?
The consensus EPS estimate for the next earnings of BIONDVAX PHARMACEUTICALS-ADR (BVXV) is -1.01 USD and the consensus revenue estimate is 0 USD.
What is the consensus rating for BVXV stock?
The consensus rating for BIONDVAX PHARMACEUTICALS-ADR (BVXV) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.